MHRA

#Clinical trials #Drug discovery #MHRA #UK

UK to introduce clinical trial reforms  

New clinical trial regulations are coming into effect this week (28 April) in the UK, with the changes being the largest package of reforms in over 20 years.   Delivered by the Medicines and Healthcare products Regulatory Agency (MHRA) and Health Research Authority (HRA), the changes will include faster assessment… Read More

#News

#Antibody drug conjugate (ADC) #Cytokine Release Syndrome (CRS) #Diabetes #Eli Lilly #GLP-1 #Idiopathic pulmonary fibrosis #Lung disease #Mergers and acquisitions #MHRA #Obesity #Poolbeg Pharma #Respiratory #Weight loss

DDW Highlights: 28 April 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, an obesity drug proved it could improve liver health independent of weight… Read More

#Podcasts

#Antibody drug conjugate (ADC) #Cytokine Release Syndrome (CRS) #Diabetes #Eli Lilly #GLP-1 #Idiopathic pulmonary fibrosis #Lung disease #Mergers and acquisitions #MHRA #Obesity #Poolbeg Pharma #Respiratory #Weight loss

This week in Drug Discovery (20 – 24 April) 

News round-up for 20 – 24 April by Bruno Quinney, Content Team at DDW.  This week, an obesity drug could improve liver health independent of weight loss. Elsewhere, Lilly is back in the news for both its type 2 diabetes drug and the company’s latest acquisition.  The top stories:   … Read More

#News

Ovarian cancer cells
#MHRA #Ovarian cancer

MHRA approves clinical trial for ovarian cancer therapy 

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved a clinical trial application for a therapy targeting advanced high-grade serous ovarian cancer.  CryptiVax-1001, developed by biotechnology company Epitopea, is an off-the-shelf mRNA therapeutic vaccine. It is designed to drive targeted immune responses using a set of tumour-specific antigens chosen for broad… Read More

#Cancer Research #News #Regulatory

Cytokine release syndrome
#Clinical Trial Authorisation #Cytokine Release Syndrome (CRS) #MHRA #Poolbeg Pharma

MHRA grants trial authorisation to CRS therapy 

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Clinical Trial Authorisation to a potential preventative therapy for Cytokine Release Syndrome (CRS).  The TOPICAL trial will investigate Poolbeg Pharma’s therapy, POLB 001, in approximately 30 relapsed/refractory multiple myeloma patients receiving the approved bispecific antibody teclistamab.  Previous research showed POLB 001, if approved,… Read More

#News #Regulatory

#BioTrinity #Investment #MHRA #Regulatory #UK

Key takes from BioTrinity 2026

DDW Editor Reece Armstrong attended day one of BioTrinity. Here he offers an overview of the conference and the themes to come out of it.   In an era of turbulence, BioTrinity stood out with an air of general positivity concerning the UK’s current standing within the life sciences sector. Though… Read More

#Business & Investment #Exclusive Content

#Animal testing #MHRA #New approach methodologies (NAMs) #Regulatory

MHRA to offer early review of non-animal data  

The Medicines and Healthcare products Regulatory Agency (MHRA) will offer early review of non-animal data in a decision supporting the government’s strategy to reduce animal testing in drug development.   The move is intended to help drug developers make greater use of New Approach Methodologies (NAMs), hopefully giving developers… Read More

#News

#CureLab Oncology #DNA #endogene.bio #Endometriosis #Genetics #Junevity #MHRA #Ocular diseases #Oncology #Regulatory #UK government #University of California San Francisco #Women's health

DDW Highlights: 20 January 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, new research in women’s health uncovered significant findings related to endometriosis and… Read More

#Podcasts

#CureLab Oncology #DNA #endogene.bio #Endometriosis #Genetics #Junevity #MHRA #Ocular diseases #Oncology #Ovarian cancer #Regulatory #UK government #University of California San Francisco #Women's health

This week in Drug Discovery (12 – 16 January) 

News round-up for 12 – 16 January by Bruno Quinney, Content Team at DDW.  This week in DDW, new research in women’s health has uncovered significant findings related to endometriosis and ovarian cancer. Elsewhere, can ageing be reversed?  The top stories:    Discovery reveals endometriosis is not… Read More

#News

#ABPI #ALS #Animal models #Cancer research #Covid-19 #Investment #Life sciences #MHRA #MND #mRNA-based vaccines

DDW Highlights: 18 November 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, groundbreaking research showed the Covid-19 mRNA vaccine could boost cancer response. Elsewhere,… Read More

#Podcasts

#ABPI #ALS #Animal models #Cancer research #Covid-19 #Investment #Life sciences #MHRA #MND #mRNA-based vaccines

This week in Drug Discovery (10 – 14 November) 

News round-up for 10 – 14 November by Bruno Quinney, Content Team at DDW.  This week’s top story comes from groundbreaking research showing the Covid-19 mRNA vaccine boosts the immune system’s cancer response. The theme of UK investment dominates other headlines, while a report shows an effective… Read More

#News

Patient receiving eye drops
#MHRA #Myopia #UK

MHRA approves myopia treatment for children in UK 

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ryjunea (low-dose atropine) to slow the progression of myopia in children.  The drug, developed by pharmaceutical company Santen, becomes the first licensed treatment to slow childhood myopia. The approval follows authorisation by the European Commission and the launch in… Read More

#News #Regulatory

MHRA
#MHRA #Rare disease #Rare diseases #UK

UK commits to major regulatory reform for rare therapies

The rulebook for rare disease therapies will be overhauled to make it quicker and easier to get these therapies tested, manufactured and approved in the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) has announced.  The announcement came in a new paper supporting the ambitions of the UK Government’s… Read More

#News #Regulatory

MHRA
#Biogen #Clinical trials #Mental health #MHRA #Regulatory #UK

Treatment for post-natal depression authorised in UK

The first targeted treatment for post-natal depression (PND) has been authorised for use in the UK through the approval of Biogen’s zuranolone by the Medicines and Healthcare Products Regulatory Agency (MHRA). Biogen state that the marketing authorisation by the MHRA addresses a critical, unmet need in maternal health due to… Read More

#News

Human kidneys
#Kidney disease #MHRA #Nephrology #Phase I trial #Purespring Therapeutics

UK approval for Purespring’s precision nephrology trial

Purespring Therapeutics’ UK Clinical Trial Application (CTA) for a planned Phase I/II study of PS-002 in patients with IgA nephropathy (IgAN) has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA), the NHS Health Research Authority (HRA) and Research Ethics Committee (REC).  PS-002 was developed to target… Read More

#News #Regulatory